trastuzumab

Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO

Rachel Johnson Terry Mamounas William Gradishar Withhold Trastuzumab in Low-Risk Patients with HER-2 Positive Breast Cancer? REFERENCE: Abstract: 2090 RACHEL JOHNSON, Christie Hospital, Manchester Som

IAN SMITH, Royal Marsden Hospital, London REFERENCE: Lancet 369:29 Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in th

Dennis Slamon George Peoples James Holland Massimo Christofanilli Trastuzumab: Mature Results in Early Breast Cancer Show Superiority REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 52

Clifford Hudis Mark Einstein Tony Greco James Berenson Edward Ambinder Breast Cancer: HER2 Still a Useful Target After Trastuzumab Resistance REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 Nov

David Cameron Martine Piccart Eric Van Cutsem Jim Cassidy Volker Heinemann Lapatinib Better for Patients with HER2+ Refractory Breast Cancer Pre-treated with Chemotherapy and Trastuzumab REFERENCE: ES

Gordon McVie Martine Piccart Bella Kaufman Jean-Yves Douillard ESMO Congress Reviewed GORDON MCVIE, European Institute of Oncology, Milan In Istanbul, Gordon McVie gave his opinion about the achieveme

Robert Ozols William See Ruth Lupu Improving on Standard Treatment in Ovarian Cancer: Have We Hit a Wall? REFERENCE: Abstract 5002, 2006 ASCO Annual Meeting; N Engl J Med 2006, 354:34-43 ROBERT OZOLS,